Product: Nodify CDT
-
Validation of a High-Specificity Blood Autoantibody Test to Detect Lung Cancer in Pulmonary Nodules
-
Lung cancer associated autoantibody responses are detectable years before clinical presentation
-
Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Commercial Payer Setting
-
Budget Impact of a Blood-Based Auto-Antibody Test to Up-Classify Risk of Pulmonary Nodules in a US Medicare Payer Setting
-
Validation of a high specificity blood based autoantibody test to detect lung cancer in pulmonary nodules
-
A Blood-Based Autoantibody Test to Help Identify Likely Malignant Indeterminate Pulmonary Nodules: An opportunity for early diagnosis of lung cancer
-
Identification of Likely Malignant Indeterminate Pulmonary Nodules by Analysis of Autoantibodies Against Lung Cancer Associated Antigens
-
Tumor-Associated Autoantibodies: Re-Optimization of Nodify CDT Diagnostic Performance and its Application to Indeterminate Pulmonary Nodules
-
Cost-effectiveness of an autoantibody test as an aid to early diagnosis of lung cancer in patients with incidentally detected pulmonary nodules
-
Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer